CN118063429A - 作为btk抑制剂的吡啶酰胺类化合物 - Google Patents
作为btk抑制剂的吡啶酰胺类化合物 Download PDFInfo
- Publication number
- CN118063429A CN118063429A CN202311563071.8A CN202311563071A CN118063429A CN 118063429 A CN118063429 A CN 118063429A CN 202311563071 A CN202311563071 A CN 202311563071A CN 118063429 A CN118063429 A CN 118063429A
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- synthesis
- btk
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124291 BTK inhibitor Drugs 0.000 title claims description 4
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical class NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 284
- 239000003814 drug Substances 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 239000012453 solvate Substances 0.000 claims abstract description 11
- -1 4-phenoxyphenyl Chemical group 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 20
- 229910052805 deuterium Inorganic materials 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 108091008875 B cell receptors Proteins 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010033078 Otitis media Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 201000002661 Spondylitis Diseases 0.000 claims description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims description 2
- 208000001435 Thromboembolism Diseases 0.000 claims description 2
- 206010043781 Thyroiditis chronic Diseases 0.000 claims description 2
- 206010048873 Traumatic arthritis Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000007803 itching Effects 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000004235 neutropenia Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 206010035653 pneumoconiosis Diseases 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 201000001223 septic arthritis Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 231100000378 teratogenic Toxicity 0.000 claims description 2
- 230000003390 teratogenic effect Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract description 26
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract description 26
- 239000003112 inhibitor Substances 0.000 abstract description 3
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 abstract description 3
- 150000004677 hydrates Chemical class 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 92
- 238000003786 synthesis reaction Methods 0.000 description 90
- 238000000034 method Methods 0.000 description 36
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 21
- 229940079593 drug Drugs 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 15
- MZPVEMOYADUARK-UHFFFAOYSA-N 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=C(C2CCN(CC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 MZPVEMOYADUARK-UHFFFAOYSA-N 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 231100000304 hepatotoxicity Toxicity 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 206010019851 Hepatotoxicity Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 7
- 230000007686 hepatotoxicity Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 229940071705 orelabrutinib Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 125000004431 deuterium atom Chemical group 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000036267 drug metabolism Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000678 effect on lipid Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UCCUXODGPMAHRL-UHFFFAOYSA-N 1-bromo-4-iodobenzene Chemical compound BrC1=CC=C(I)C=C1 UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 1
- LFCADBSUDWERJT-UHFFFAOYSA-N 2,6-dichloropyridine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)C(Cl)=N1 LFCADBSUDWERJT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WHYUAGZAHLUISP-UHFFFAOYSA-N [1-[(2-methylpropan-2-yl)oxycarbonyl]-3,6-dihydro-2h-pyridin-4-yl]boronic acid Chemical group CC(C)(C)OC(=O)N1CCC(B(O)O)=CC1 WHYUAGZAHLUISP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007837 negative regulation of B cell activation Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及作为布鲁顿酪氨酸激酶(BTK)抑制剂的吡啶酰胺类化合物。具体而言,本发明公开了2‑(4‑苯氧基苯基)‑6‑[1‑(丙‑2‑烯酰)哌啶‑4‑基]吡啶‑3‑甲酰胺和/或其互变异构体的氘代化合物,其晶型、其盐、其水合物或溶剂合物的药物组合物,以及它们作为BTK相关的疾病的预防和/或治疗剂。
Description
技术领域
本发明属于生物医药领域,具体涉及一种作为BTK抑制剂的吡啶酰胺类化合物。
背景技术
经B细胞受体(BCR)的B细胞信号转导能产生广泛的生物学输出信号,异常的BCR介导的信号转导能造成失调的B细胞活化和/或形成导致多种自身免疫疾病和/或炎性疾病的致病性自身抗体。人体内BTK的突变导致X连锁无Y球蛋白血症(XLA)(Conley等人,Annu.Rev.Immunol.27:199-227,2009)。这种疾病与B细胞成熟受损、免疫球蛋白产生减少、不依赖T细胞的免疫应答受损以及在BCR刺激时持续的钙信号的显著减弱有关。
抑制BTK活性可以用于治疗***反应性疾病和/或自身免疫疾病和/或炎性疾病,例如:类风湿性关节炎、多血管炎、特发性血小板减少性紫殿(ITP)、重症肌无力、变应性鼻炎和哮喘(Di Paolo等人(2011)Nature Chem.Biol.7(1):41-50;Liu等人(2011)Jour.ofPharm.and Exper.Ther.338(1):154-163)。
此外,BTK的异常活化在B细胞淋巴瘤的发病机制中起着重要的作用,这意味着在血液恶性肿瘤的治疗中抑制BTK是有很有用的(Davis等人,Nature 463:88-92,2010)。由于BTK作为介体在多个信号转导通路中起着核心作用,因此,抑制BTK活性可抗炎和/或抗癌,用于癌症及治疗B细胞淋巴瘤、白血病和其它血液恶性肿瘤(Mohamed等人,Immunol.Rev.228:58-73,2009;Pan,DrugNews perspect 21:357-362,2008;Rokosz等人,Expert Opin.Ther.Targets12:883-903,2008;Uckun等人,Anti-cancerAgentsMed.Chem.7:624-632,2007;Lou等人,J.Med.Chem.55(10):4539-4550,2012)。
2-(4-苯氧基苯基)-6-[1-(丙-2-烯酰)哌啶-4-基]吡啶-3-甲酰胺(奥布替尼,Orelabrutinib,ICP-022),是布鲁顿酪氨酸激酶(BTK)抑制剂,用于治疗淋巴瘤、白血病及自身免疫性疾病。其在大鼠体内的消除半衰期为8.25小时(Ya-nan Liu等人(2022),Frontiers in Pharmacology.10.3389/fphar.2022.991281),而奥布替尼药物代谢和动力学对药效和/或毒性的影响仍不是十分清楚,存在改进的可能性。
目前一些药物的不太好的药物代谢和动力学性能,如:吸收、分布、代谢和/或***,妨碍了它们更广泛的使用或限制了它们在特定适应症中的应用。例如,由于药物在体内的较快清除,常采用的解决办法是频繁地给药或给予高剂量的药物以获得足够高的药物血浆水平。然而,这引入了大量潜在的治疗问题,如患者对于服药间隔的顺应性,以及较高的剂量给药,副作用会更加严重,并且增加了治疗成本。
人们尝试通过氘修饰(改性)减缓药物的代谢,或通过用氘原子取代一个或多个氢原子以减少不期望的代谢物的形成等,从而改善药物的药物代谢和动力学性能。氘是氢的一种安全、稳定、非放射性的同位素。与氢相比,氘与碳形成更强的化学键。在选定的情况下,由氘赋予的增加的键强度可以改善药物的药物代谢和动力学性能,具有改进药效、安全性、和/或耐受性的可能性。同时,由于氘的大小和形状基本上等同于氢,与仅包含氢的原始化学实体相比,预期用氘取代氢将不影响药物的生物化学效能和选择性。
但是,由于生物***的代谢过程复杂,药物在生物体内的药代动力学性质受到多方面因素影响,也表现出相应的复杂性。与相应的非氘代药物相比,氘代药物药代动力学性质的变化表现出极大的偶然性和不可预测性。对于一些化合物,氘代减慢了其在体内的代谢清除、半衰期增长;对于其它化合物,氘代没有引起代谢改变;对于另一些其它化合物,氘代加快了代谢清除,半衰期缩短(Blake,MI et al,J Pharm Sci,1975,64:367-91;Foster,AB,Adv Drug Res 1985,14:1-40("Foster");Kushner,DJ et al,Can J PhysiolPharmacol 1999,79-88;Fisher,MB et al,Curr Opin Drug Discov De ve l,2006,9:101-09("Fisher"))。
故化合物某些位点的氘代非但不能增长半衰期,反而可能会使其缩短(ScottL.Harbeson,Roger D.Tung.Deuteriumin Drug Discovery andDevelopme nt,P405-406),劣化其药代动力学性质;另一方面,药物分子上某些位置的氢因为空间位阻等原因也不易被氘代。
甚至当将氘原子并入已知代谢位点时,氘修饰(氘改性)对药物的代谢的影响也不是可预测的。只有通过实际制备和测试氘代的药物,才能确定代谢的速率将是否和怎样不同于非氘代的对应的化学实体。许多药物具有可能代谢的多个部位。需要氘取代的位置(部位)和发现影响代谢所必需的氘化程度,如果有,对于每种药物将是不同的(Fukuto etal.J.Med.Chem.1991,34,2871-76)。
如前所述,氘修饰(氘改性)对药物的代谢的影响是不可预测的。奥布替尼及其体内代谢产物具有肝毒性风险的缺陷,且奥布替尼的临床实验也显示了肝毒性,引起很大的临床担忧。肝毒性不仅与化学结构有关,且与临床给药剂量也密切相关。
因此,针对现有技术的不足,我们设计新化合物,提高新化合物在体内的暴露量,减小用药剂量和/或频率,减小肝毒性;和/或通过结构改造,降低其原形或代谢物的肝毒性,或减少其毒性代谢物的生成,从而达到减毒增效的目的。
发明内容
本发明的目的是提供一类新型的具有BTK抑制活性的吡啶酰胺类化合物及其用途。
在本发明的第一方面,提供了一种式Ⅰ的吡啶酰胺类化合物、其互变异构体、其晶型、其盐、其水合物或溶剂合物
其中:
R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18或R19各自独立的选自氢(H)或氘(D),条件是R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18或R19中至少一个是氘。
在一优选例中,所述化合物为权利要求1所述的化合物,为下列的化合物P001、化合物P002、化合物P003、化合物P004和化合物P005。
在另一优选例中,所述化合物为权利要求1所述的化合物,为下列的化合物P006、化合物P007、化合物P008、化合物P009、化合物P010、化合物P011、化合物P012、化合物P013、化合物P014和化合物P015。
在本发明的第二方面,提供了一种制备药物组合物的方法,包括步骤:将药学上可接受的载体与本发明中第一方面所述的化合物,其互变异构体、其晶型、其盐、其水合物或溶剂合物进行混合,从而形成药物组合物。
在本发明的第三方面,提供了一种药物组合物,它含有药学上可接受的载体与本发明中第一方面所述的化合物,其互变异构体、其晶型、其盐、其水合物或溶剂合物。
在本发明的第四方面,提供了本发明第一方面中所述的化合物,其互变异构体、其晶型、其盐、其水合物或溶剂合物的用途,它们被用于制备抑制BTK的药物组合物。
在另一优选例中,所述的药物组合物用于预防和/或治疗与BTK相关的疾病。
在另一优选例中,所述的药物组合物用于预防和/或治疗与BTK相关的疾病为***反应性病症、自身免疫性疾病、炎性疾病、血栓栓塞性疾病或癌症。
在另一优选例中,所述的药物组合物用于治疗类风湿性关节炎、银屑病性关节炎、感染性关节炎、进行性慢性关节炎、致畸性关节炎、骨关节炎、创伤性关节炎、痛风性关节炎、Reiter氏综合症、多软骨炎、急性滑膜炎、脊椎炎、有肾病综合症的肾小球肾炎、没有肾病综合症的肾小球肾炎、自身免疫性血液***病症、溶血性贫血、再生障碍性贫血、特发性血小板减少症、嗜中性白血球减少症、自身免疫性胃炎、自身免疫性炎性肠病、溃病性结肠炎、Crohn氏病、宿主抗移植物病、同种异体移植物排斥、慢性甲状腺炎、格雷夫斯氏病、硬皮病、I型糖尿病、II型糖尿病、急性活动性肝炎、慢性活动性肝炎、胰腺炎、原发性胆汁性肝硬化、重症肌无力、多发性硬化症、***性红斑狼疮、银屑病、特应性皮炎、接触性皮炎、湿痒、皮肤晒伤、血管炎、Behcet氏病、慢性肾功能不全、Stevens-Johnson综合症、炎性痛、特发性脂肪泻、恶病质、结节病、Guillain-Barré综合症、葡萄膜炎、结膜炎、角膜结膜炎、中耳炎、牙周病、肺间质性纤维化、哮喘、支气管炎、鼻炎、窦炎、尘肺病、肺功能不全综合症、肺气肿、肺纤维化、砂肺、慢性炎性肺病、慢性阻塞性肺病、增生性疾病、非霍奇金淋巴瘤、弥漫性大B细胞淋巴瘤(DLBCL)、套细胞淋巴瘤(MCL)、B细胞慢性淋巴细胞性白血病、急性成淋巴细胞性白血病、具有成熟B细胞的急性成淋巴细胞性白血病、由慢性活动型B细胞受体信号传导引起的B细胞淋巴瘤和与多发性骨髓瘤相关的骨病。
在另一优选例中,所述的药物组合物用于治疗慢性淋巴细胞性淋巴瘤、非霍奇金淋巴瘤、弥漫性大B细胞淋巴瘤、套细胞淋巴瘤、滤泡性淋巴瘤和慢性淋巴细胞白血病。
如本文所用,“氘代”指化合物或基团中的一个或多个氢被氘所取代。氘代可以是一取代、二取代、多取代或全取代。
在另一优选例中,氘在氘取代位置的氘同位素含量是大于天然氘同位素含量(0.015%),更佳地大于50%,更佳地大于85%,更佳地大于95%,更佳地大于99%,更佳地大于99.5%。
在另一优选例中,式I化合物至少含有1或3个氘原子,更佳地5或8个氘原子。
如本文所用,术语“本发明化合物”指式I所示的化合物。该术语还包括式I化合物的互变异构体、其晶型、其盐、其水合物或溶剂合物。
如本文所用,术语“药学上可接受的盐”指本发明化合物与酸或碱所形成的适合用作药物的盐。药学上可接受的盐包括无机盐和有机盐。一类优选的盐是本发明化合物与酸形成的盐。适合形成盐的酸包括但并不限于:盐酸、氢溴酸、氢氟酸、硫酸、硝酸、磷酸等无机酸,甲酸、乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、拧檬酸、苦味酸、甲磺酸、苯甲磺酸,苯磺酸等有机酸;以及天冬氨酸、谷氨酸等酸性氨基酸。
本发明化合物或其药学上可接受的衍生物也可在投予一种或多种其它治疗剂的同时、之前或之后投予。此组合疗法包括投予含有本发明化合物和一种或多种其它活性剂的单一药学给药制剂,以及投予本发明化合物与各活性剂自己的单独药学给药制剂。例如,本发明化合物与另一活性剂可以单一口服给药组合物(例如片剂或胶囊)一起投予患者,或各药剂以单独口服给药制剂投予。在使用单独给药制剂的情况下,本发明化合物与一种或多种额外活性剂可基本上在同一时间(即同时)或在单独错开的时间(即相继)投予;组合疗法应理解为包括所有这些方案。
本发明的药用组合根据疾病状态、给药途径、患者年龄或者体重的不同,给药剂量会做调整。对于成人口服给药,通常为0.2-35mg/kg/天,较佳为0.8-20mg/kg/天。本发明适宜的给药剂量需要考虑患者的年龄、体重、病情、给药途径等进行设定,口服给药通常为0.1-35mg/kg/天,较佳为0.5-15mg/kg/天范围内。
本发明的积极进步效果在于:
(1)本发明化合物具有良好的选择性BTK抑制作用,能有效用作与BTK相关的疾病。
(2)本发明化合物具有良好的选择性抑制B细胞活化作用,是一种有效用作B细胞活化抑制剂。
(3)本发明氘代的吡啶酰胺类化合物及其药学上可接受的盐肝毒性小,药代动力学性质良好、降低使用剂量和/或降低毒副作用,成药性更好。与奥布替尼相比,具有明显更优异的药物动力学和/或药效学性能和/或安全性性能,更适用制备治疗与BTK相关的疾病。
具体的实施方法
下面更具体地描述本发明式I结构化合物的制备方法,但这些具体方法不对本发明构成任何限制。本发明化合物还可以任选将在本说明书中描述的或本领域已知的各种合成方法组合起来而方便的制得,这样的组合可由本发明所属领域的技术人员容易的进行。
本发明使用的未氘代的吡啶酰胺类化合物及其生理上相容的盐的制备方法是已知的。对应氘代的吡啶酰胺类化合物可以用相应的氘代起始化合物为原料,用相同的路线合成。
以化合物P001为例,一种优选的制备流程如下:
其具体合成方法在实施例1中说明。
下面结合具体实施例,进一步阐述本发明。这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。
实施例1:化合物P001的合成
合成路线
步骤1:化合物P102的合成
在浓硫酸(10ml)和水(2ml)的混合溶液中,加入2,6-二氯尼古丁腈(化合物P101)(10mmol),加热到90℃,搅拌l小时。冷却至室温后,将反应混合物置于冰水浴中,用氨水调节PH值至8。过滤,滤饼用水洗涤,干燥后得到化合物P102。
步骤2:化合物P104的合成
在1,4-二氧六环(60ml)和水(12ml)混合溶液中,加入化合物P102(3.0mmol)、4-苯氧基苯基硼酸-d5(化合物P103)(3.0mmol)、三(二亚苄基丙酮)二钯(0.55mmol)、碳酸铯(6.0mmol)后,加热到120℃,回流搅拌16小时。减压浓缩,残余物用硅胶柱纯化,洗脱剂为二氯甲烷/甲醇(150/1),去除溶剂,得化合物P104。
步骤3:化合物P106的合成
在乙二醇二甲醚(l0ml)和水(2ml)的混合溶液中,加入化合物P104(0.50mmol)、(1-(叔丁氧基羰基)-1,2,3,6-四氢吡啶-4-基)硼酸(化合物P105)(0.75mmol)、四(三苯基膦)钯(0.lmmol)和碳酸钾(l.5mmol),加热到90℃,搅拌5小时。冷却至室温,减压浓缩,残余物用硅胶柱纯化,洗脱剂为二氯甲烷/甲醇(700/1),去除溶剂,得化合物P106。
步骤4:化合物P107的合成
在乙酸乙酯(10ml)中,加入化合物P106(0.45mmol)和钯碳(10mg),在除去氧的氢气气氛下室温搅拌16小时。减压浓缩,残余物用硅胶柱纯化,洗脱剂为二氯甲烷/甲醇(70/1),去除溶剂,得化合物P107。
步骤5:化合物P108的合成
在二氯甲烷(5ml)中,加入化合物P107和三氟乙酸(2ml),室温下搅拌l小时。减压浓缩,残余物溶解于二氯甲烷,用饱和碳酸氢钠溶液洗涤。有机相用无水硫酸钠干燥,过滤除去干燥剂,减压浓缩,残余物用硅胶柱纯化,洗脱剂为二氯甲烷/甲醇(70/1到5/1),合并目标产物馏分,去除溶剂,得化合物P108。
步骤6:化合物P001的合成
在二氯甲烷(6ml)中,加入化合物P108(0.40mmol)、烯丙酰氯-d3(化合物P109)(0.56mmol)和三乙胺(0.85mmol),在0℃下搅拌l小时。反应用水(10ml)淬灭,用乙酸乙酯(30ml)稀释,依次用水(20ml×2)和饱和食盐水(20ml×2)洗涤。将有机相用无水硫酸钠干燥,过滤除去干燥剂,减压浓缩,残余物用硅胶柱纯化。洗脱剂为二氯甲烷/甲醇(20/1),去除溶剂,得化合物P001。化合物P001的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.2-6.9(3H),5.8(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例2:化合物P002的合成
化合物P002的合成,将“实施例1:化合物P001的合成”中步骤2的化合物P103改为化合物P202。其余步骤同“实施例1:化合物P001的合成”操作,得化合物P002。化合物P002的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.5-7.3(2H),7.2-6.9(5H),5.8(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例3:化合物P003的合成
化合物P003的合成,将“实施例1:化合物P001的合成”中步骤2的化合物P103改为化合物P203。其余步骤同“实施例1:化合物P001的合成”操作,得化合物P003。化合物P003的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.5-7.3(2H),7.2-6.9(3H),5.8(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例4:化合物P004的合成
化合物P004的合成,将“实施例1:化合物P001的合成”中步骤2的化合物P103改为化合物P204。其余步骤同“实施例1:化合物P001的合成”操作,得化合物P004。化合物P004的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.2-6.9(5H),5.8(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例5:化合物P005的合成
化合物P005的合成,将“实施例1:化合物P001的合成”中步骤2的化合物P103改为化合物P205。其余步骤同“实施例1:化合物P001的合成”操作,得化合物P005。化合物P005的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.5-7.3(2H),7.2-6.9(6H),5.8(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例6:化合物P006的合成
化合物P006的合成,将“实施例1:化合物P001的合成”中步骤6的化合物P109改为化合物P206。其余步骤同“实施例1:化合物P001的合成”操作,得化合物P006。化合物P006的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.2-6.9(3H),6.6(1H),6.3(1H),5.8(1H),5.7(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例7:化合物P007的合成
化合物P007的合成,将“实施例6:化合物P006的合成”中步骤2的化合物P103改为化合物P202。其余步骤同“实施例6:化合物P006的合成”操作,得化合物P007。化合物P007的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.5-7.3(2H),7.2-6.9(5H),6.6(1H),6.3(1H),5.8(1H),5.7(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例8:化合物P008的合成
化合物P008的合成,将“实施例6:化合物P006的合成”中步骤2的化合物P103改为化合物P203。其余步骤同“实施例6:化合物P006的合成”操作,得化合物P008。化合物P008的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.5-7.3(2H),7.2-6.9(3H),6.6(1H),6.3(1H),5.8(1H),5.7(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例9:化合物P009的合成
化合物P009的合成,将“实施例6:化合物P006的合成”中步骤2的化合物P103改为化合物P204。其余步骤同“实施例6:化合物P006的合成”操作,得化合物P009。化合物P009的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.2-6.9(5H),6.6(1H),6.3(1H),5.8(1H),5.7(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例10:化合物P010的合成
化合物P010的合成,将“实施例1:化合物P001的合成”中步骤2的化合物P103改为化合物P207。其余步骤同“实施例1:化合物P001的合成”操作,得化合物P010。化合物P010的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.2-6.9(4H),5.8(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例11:化合物P011的合成
化合物P011的合成,将“实施例1:化合物P001的合成”中步骤2的化合物P103改为化合物P208。其余步骤同“实施例1:化合物P001的合成”操作,得化合物P011。化合物P011的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.5-7.3(2H),7.2-6.9(4H),5.8(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例12:化合物P012的合成
化合物P012的合成,将“实施例1:化合物P001的合成”中步骤2的化合物P103改为化合物P209。其余步骤同“实施例1:化合物P001的合成”操作,得化合物P012。化合物P012的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.2-6.9(6H),5.8(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例13:化合物P013的合成
化合物P013的合成,将“实施例6:化合物P006的合成”中步骤2的化合物P103改为化合物P207。其余步骤同“实施例6:化合物P006的合成”操作,得化合物P013。化合物P013的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.2-6.9(4H),6.6(1H),6.3(1H),5.8(1H),5.7(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例14:化合物P014的合成
化合物P014的合成,将“实施例6:化合物P006的合成”中步骤2的化合物P103改为化合物P208。其余步骤同“实施例6:化合物P006的合成”操作,得化合物P014。化合物P014的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.5-7.3(2H),7.2-6.9(4H),6.6(1H),6.3(1H),5.8(1H),5.7(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例15:化合物P015的合成
化合物P015的合成,将“实施例6:化合物P006的合成”中步骤2的化合物P103改为化合物P209。其余步骤同“实施例6:化合物P006的合成”操作,得化合物P015。化合物P015的核磁共振氢谱为:1H-NMR(CDCl3)δ8.0(1H),7.8-7.6(2H),7.2-6.9(6H),6.6(1H),6.3(1H),5.8(1H),5.7(1H),5.5(1H),4.8(1H),4.1(1H),3.2(1H),3.1(1H),2.8(1H),2.0-1.9(2H),1.8-1.6(2H)。
实施例16:化合物P103的合成
步骤7:化合物P403的合成
取化合物P401(11.8g),溶于无水四氢呋喃(120ml)中,搅拌,分批次缓慢加入氢化钠(12.1g),再分批次加入1-溴-4-碘苯(化合物P402)(39.1g),室温反应15hr,将反应物过滤,滤液旋干,加入二氯甲烷溶解。过硅胶柱,用石油醚:乙酸乙酯(1:5)洗脱,得化合物P403(12.7g)
步骤8:化合物P103的合成
将化合物P403(5.2g)溶解于干燥的THF(100ml),N2保护下在-78℃反应30min,缓慢滴加正丁基锂(1.9g),滴加结束后保持-78℃反应3h,再缓慢滴加硼酸三异丙酯(4.3g),滴加结束后保持在-78℃反应2h,缓慢升至室温,反应15hr左右,TLC监测反应结束后,用水缓慢淬灭反应液,萃取浓缩,得化合物P103(3.0g)。
实施例17:化合物P203的合成
化合物P203的合成,按“实施例16:化合物P103的合成”进行,只在步骤7中,化合物P401改为化合物P402,其余步骤同“实施例16:化合物P103的合成”操作,得化合物P203。
实施例18:化合物P204的合成
化合物P204的合成,按“实施例16:化合物P103的合成”进行,只在步骤7中,化合物P401改为化合物P403,其余步骤同“实施例16:化合物P103的合成”操作,得化合物P204。
实施例19:化合物P202的合成
化合物P202的合成,按“实施例16:化合物P103的合成”进行,只在步骤7中,化合物P401改为化合物P404,其余步骤同“实施例16:化合物P103的合成”操作,得化合物P202。
实施例20:化合物P207的合成
化合物P207的合成,按“实施例16:化合物P103的合成”进行,只在步骤7中,化合物P401改为化合物P405,其余步骤同“实施例16:化合物P103的合成”操作,得化合物P207。
实施例21:化合物P208的合成
化合物P208的合成,按“实施例16:化合物P103的合成”进行,只在步骤7中,化合物P401改为化合物P406,其余步骤同“实施例16:化合物P103的合成”操作,得化合物P208。
实施例22:化合物P209的合成
化合物P209的合成,按“实施例16:化合物P103的合成”进行,只在步骤7中,化合物P401改为化合物P407,其余步骤同“实施例16:化合物P103的合成”操作,得化合物P209。
实施例23:大鼠药代动力学
30只雄性Sprague-Dawley大鼠,6-9周龄,体重约220g,分成5组(奥布替尼组、化合物P001组、化合物P002组、化合物P005组和化合物P009组),每组6只。按照分组分别单次灌胃给予10mg/kg剂量的奥布替尼、化合物P001、化合物P002、化合物P005和化合物P009,比较其药代动力学差异。
大鼠给药前12小时开始禁食。用0.5%羧甲基纤维素钠(CMC-Na)配制给药溶液。眼眶静脉丛采血,采血时间点为给药后0.25小时、0.5小时、1小时、2小时、4小时、6小时、8小时、12小时、16小时和24小时。血样分离出血浆后,将血浆保存在-80℃冰箱中备用。建立LC-MS/MS分析方法对血浆样品进行测定。
由试验结果可知,与奥布替尼相比,化合物P001、化合物P002、化合物P005和化合物P009的消除半衰期T1/2和/或曲线下面积AUC和/或最大血药浓度Cmax增加50%以上。
由本结果可知,与奥布替尼相比,本发明化合物P001、化合物P002、化合物P005和/或化合物P009在大鼠体内具有更好的药代动力学性质,预示具有更好的药效学和治疗效果。
实施例24:大鼠药代动力学
24只雄性Sprague-Dawley大鼠,6-9周龄,体重约220g,分成4组(奥布替尼组、化合物P006组、化合物P007组、化合物P012组),每组6只。按照分组分别单次灌胃给予10mg/kg剂量的奥布替尼、化合物P006、化合物P007和化合物P012,比较其药代动力学差异。
大鼠给药前12小时开始禁食。用0.5%羧甲基纤维素钠(CMC-Na)配制给药溶液。眼眶静脉丛采血,采血时间点为给药后0.25小时、0.5小时、1小时、2小时、4小时、6小时、8小时、12小时、16小时和24小时。血样分离出血浆后,将血浆保存在-80℃冰箱中备用。建立LC-MS/MS分析方法对血浆样品进行测定。
由试验结果可知,与奥布替尼相比,化合物P006、化合物P007和化合物P012的消除半衰期T1/2和/或曲线下面积AUC和/或最大血药浓度Cmax增加40%以上。
由本结果可知,与奥布替尼相比,本发明化合物P006、化合物P007和/或化合物P012在大鼠体内具有更好的药代动力学性质,预示具有更好的药效学和治疗效果。
实施例25:BTK的抑制活性测定
使用ADP-GloTM试剂盒测定本发明的化合物对BTK的活性影响。实验方法如下:
ADP是激酶反应的产物,通常可以通过检测ADP的生成量来检测激酶活性。Promega公司开发的ADP-GloTM试剂盒即是通过检测激酶反应中所产生的ADP水平来测定BTK的体外活性。在激酶检测实验中,激酶消耗ATP将底物磷酸化,同时产生ADP。然后加入ADP-Glo试剂终止激酶反应并且将剩余的ATP完全消耗。再加入激酶检测试剂,将产生的ADP转化为新的ATP,检测试剂中的萤光素酶在ATP和O2参与下能够催化荧光素,产生光信号,从而将化学信号转为光信号,且光信号的强度与激酶反应中ADP产生的量呈正相关,从而能够定量检测激酶BTK的活性。
所有检测实验均在23℃恒室温进行,使用Corning 3674白色384孔检测板,激酶BTK(Invitrogen公司),激酶底物为多肽(4:l Glu,Tyr)(Signal Chem)和ATP(Sigma),使用酶标仪EnVision(Perkin Elmer)读取光信号。检测缓冲液包括40mM Tris-HCl(pH 7.5)、10mM MgCl2(Sigma)、2mM MnCl2(Sigma)、0.05mM DTT(Sigma)和0.01%BSA(Sigma);将激酶BTK使用检测缓冲液配制为1.3ng/μL浓度的激酶反应溶液;底物反应溶液包括0.25mg/mL多肽底物和60μMATP。
将本发明的化合物用DMSO稀释成0.5mM的溶液,然后用DMSO进行三倍梯度稀释至最低浓度为0.025μM,用Echo555向384孔板中先添加50nL系列浓度的化合物溶液和2.5μL激酶反应溶液,混合均匀后室温避光孵育30分钟;随后加入2.5μL底物反应溶液,反应总体积为5.05μL,将反应混合物在室温避光反应60分钟;随后加入5μLADP-GloTM试剂终止反应,混合均匀后室温放置40分钟;最后加入10μL激酶检测试剂,室温避光放置30分钟,然后在Envision上读取数值。
抑制百分率按以下公式计算:
抑制%=[1-(RLU化合物-RLUmin)/(RLUmax-RLUmin)]×100
其中RLU化合物为本发明化合物的给定浓度下的读数,RLUmin为不加入激酶BTK的情况下的读数,RLUmax为不加入本发明化合物的情况下的读数。通过使用Excel中XLfit程序计算化合物的IC50值。
表1:本发明化合物的IC50值
化合物 | IC50(nM) | 化合物 | IC50(nM) |
P001 | 1.4 | P002 | 2.7 |
P006 | 2.4 | P007 | 1.9 |
P008 | 2.6 | P012 | 3.1 |
P015 | 3.4 | Orelabrutinib | 3.9 |
由本结果可知,本发明化合物对BTK具有明显的抑制效应。
实施例26:小鼠肝毒性对比研究
(1)实验动物
选择成年雄性ICR小鼠32只,体重(25±2g),所有小鼠允许自由进食水和维持饲料,25±2℃的温度,50±10%的相对湿度下昼夜交替循环。
(2)动物分组与给药
32只雄性ICR小鼠分为四组,每组8只,分别为正常对照组、模型组、模型+实施例化合物组和模型+Orelabrutinib组。模型+实施例化合物组按剂量(50mg/kg)每天灌胃给药一次实施例化合物;模型+Orelabrutinib组按剂量(50mg/kg)每天灌胃给药一次Orelabrutinib,分别持续8-16周,正常对照组和模型组分别灌胃等体积纯净水。末次给药后开始断粮,1h后对模型组、模型+实施例化合物组和模型+Orelabrutinib组小鼠分别一次性腹腔注射250mg/kg的对乙酰氨基酚(APAP)生理盐水溶液,造模24h后依次对各组小鼠进行眼球取血,3000r/min离心10min分离血清,4℃保存备用;迅速解剖取肝脏及脾脏。经4℃生理盐水冲洗,滤纸吸干,称重,取部分肝脏于10%的甲醛溶液中固定,待切片,剩余肝脏-80℃低温冰箱中保存。
(3)肝脏中生化指标的测定:
取部分肝脏称重,加入9倍体积的冰生理盐水,用组织匀浆机制得10%的肝组织匀浆,离心取上清液。按照试剂盒方法点板,在450nm处测定OD值,根据公式计算肝脏中MDA的含量和GSH的活性。
(4)数据处理
实验数据均用均数±标准差(±s)表示,用SPSS22.0统计软件进行分析,组间采用单因素方差分析比较差异。P<0.05位明显差异。
(5)本申请实施例化合物对APAP肝损伤小鼠肝组织脂质过氧化影响
与正常对照组相比,模型组小鼠肝组织匀浆中MDA含量明显的上升,GSH水平显著下降(P<0.05),使小鼠体内脂质过氧化产物累积,抗氧化代谢水平降低;与模型组相比,模型+实施例化合物组的MDA含量和GSH水平均无明显变化(P>0.05);与模型组相比,模型+Orelabrutinib组的MDA含量明显的上升(P<0.05),GSH水平显著下降(P<0.05),表明本申请实施例化合物(50mg/kg)对APAP引起的脂质过氧化没有明显影响,而Orelabrutinib(50mg/kg)对APAP引起的脂质过氧化有影响,提示本申请实施例化合物的小鼠肝脏毒性小于Orelabrutinib。结果如表2所示。
表2.对APAP肝损伤小鼠肝组织脂质过氧化影响
分组 | MDA(nmol/mg) | GSH(μmol/L) |
正常对照组 | A- | B- |
模型组 | A+ | B+ |
模型+实施例化合物组 | A+ | B+ |
模型+Orelabrutinib组 | A++ | B++ |
标注(等级):A+为2.4-3.5;A-为1.5-2.2;A++为3.8-5.2;B+为28-39;B-为42-52;B++为16-27。
结论:本申请实施例化合物(50mg/kg)对APAP引起的脂质过氧化没有明显影响,而Orelabrutinib(50mg/kg)对APAP引起的脂质过氧化有影响,提示本申请实施例化合物的小鼠肝脏毒性小于Orelabrutinib。
最后有必要说明的是,以上对本发明的具体实施例进行了详细描述,但其只作为范例,本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言,任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所作的均等变换和修改,都应涵盖在本发明的范围内。
Claims (8)
1.本发明提供一种式Ⅰ的吡啶酰胺类化合物、其互变异构体、其晶型、其盐、其水合物或溶剂合物
其中:
R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18或R19各自独立的选自氢或氘,条件是R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18或R19中至少一个是氘。
2.权利要求1所述的化合物,其互变异构体、其晶型、其盐、其水合物或溶剂合物,其特征在于所述化合物选自以下结构:
3.一种药物组合物,其包含药学上可接受的载体与权利要求1-2中任一所述的化合物,其互变异构体、其晶型、其盐、其水合物或溶剂合物。
4.权利要求1-2中任一项的吡啶酰胺类化合物,其互变异构体、其晶型、其盐、其水合物或溶剂合物在制备BTK抑制剂上的应用。
5.权利要求3所述的药物组合物在制备治疗和/或预防与BTK相关的疾病的药物上的应用。
6.权利要求5所述的药物组合物,其中,与BTK相关的疾病为***反应性病症、自身免疫性疾病、炎性疾病、血栓栓塞性疾病或癌症。
7.权利要求1-2中任一项的化合物,其互变异构体、其晶型、其盐、其水合物或溶剂合物用于制备用于治疗BTK介导的病症的药物的用途,其中所述BTK介导的病症选自:类风湿性关节炎、银屑病性关节炎、感染性关节炎、进行性慢性关节炎、致畸性关节炎、骨关节炎、创伤性关节炎、痛风性关节炎、Reiter氏综合症、多软骨炎、急性滑膜炎、脊椎炎、有肾病综合症的肾小球肾炎、没有肾病综合症的肾小球肾炎、自身免疫性血液***病症、溶血性贫血、再生障碍性贫血、特发性血小板减少症、嗜中性白血球减少症、自身免疫性胃炎、自身免疫性炎性肠病、溃病性结肠炎、Crohn氏病、宿主抗移植物病、同种异体移植物排斥、慢性甲状腺炎、格雷夫斯氏病、硬皮病、I型糖尿病、II型糖尿病、急性活动性肝炎、慢性活动性肝炎、胰腺炎、原发性胆汁性肝硬化、重症肌无力、多发性硬化症、***性红斑狼疮、银屑病、特应性皮炎、接触性皮炎、湿痒、皮肤晒伤、血管炎、Behcet氏病、慢性肾功能不全、Stevens-Johnson综合症、炎性痛、特发性脂肪泻、恶病质、结节病、Guillain-Barré综合症、葡萄膜炎、结膜炎、角膜结膜炎、中耳炎、牙周病、肺间质性纤维化、哮喘、支气管炎、鼻炎、窦炎、尘肺病、肺功能不全综合症、肺气肿、肺纤维化、砂肺、慢性炎性肺病、慢性阻塞性肺病、增生性疾病、非霍奇金淋巴瘤、弥漫性大B细胞淋巴瘤、套细胞淋巴瘤、B细胞慢性淋巴细胞性白血病、急性成淋巴细胞性白血病、具有成熟B细胞的急性成淋巴细胞性白血病、由慢性活动型B细胞受体信号传导引起的B细胞淋巴瘤和与多发性骨髓瘤相关的骨病。
8.根据权利要求7的用途,其中所述BTK介导的病症是B细胞增殖性疾病,选自慢性淋巴细胞性淋巴瘤、非霍奇金淋巴瘤、弥漫性大B细胞淋巴瘤、套细胞淋巴瘤、滤泡性淋巴瘤和慢性淋巴细胞白血病。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022114698371 | 2022-11-23 | ||
CN202211469837 | 2022-11-23 | ||
CN2023115327119 | 2023-11-17 | ||
CN202311532711 | 2023-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118063429A true CN118063429A (zh) | 2024-05-24 |
Family
ID=91104784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311563071.8A Pending CN118063429A (zh) | 2022-11-23 | 2023-11-22 | 作为btk抑制剂的吡啶酰胺类化合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN118063429A (zh) |
WO (1) | WO2024109789A1 (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2682043T3 (es) * | 2012-07-30 | 2018-09-18 | Concert Pharmaceuticals Inc. | Ibrutinib deuterado |
SI3052476T1 (sl) * | 2013-09-30 | 2020-12-31 | Guangzhou Innocare Pharma Tech Co., Ltd. | Substituirani nikotinimidni inhibitorji BTK in njihova priprava in uporaba pri zdravljenju raka, vnetja in avtoimunske bolezni |
-
2023
- 2023-11-22 CN CN202311563071.8A patent/CN118063429A/zh active Pending
- 2023-11-22 WO PCT/CN2023/133130 patent/WO2024109789A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024109789A1 (zh) | 2024-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2931722B1 (en) | Substituted 1h-pyrrolo [2,3-b]pyridine and 1h-pyrazolo [3, 4-b]pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors | |
CN115335379A (zh) | 含螺环的喹唑啉化合物 | |
KR101701533B1 (ko) | 아이속사졸-피리다진 유도체 | |
CN109310675A (zh) | 治疗性抑制化合物 | |
EP1661897A1 (en) | Pyrrolopyrimidinone derivative | |
AU2014250392B2 (en) | Salt of pyrazoloquinoline derivative, and crystal thereof | |
TW200911816A (en) | Novel 6-triazolopyridazine sulphanyl benzothiazole and benzimidazole derivatives, process for preparing same, use thereof as medicaments, pharmaceutical compositions and novel use especially as met inhibitors | |
EP3842431B1 (en) | [1,2,4]triazolo[1,5-a]pyridine compound as jak inhibitor and application thereof | |
JP7473642B2 (ja) | Btk阻害剤としてのピロロピリミジン系化合物およびその使用 | |
CN108721298A (zh) | 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用 | |
WO2015195880A1 (en) | Imidazo-pyridazne derivatives as casein kinase 1 delta/epsilon inhibitors | |
JP2023504866A (ja) | 大環構造を有するフッ素含有複素環誘導体およびその用途 | |
AU2016263472B2 (en) | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol | |
IL267829A (en) | New Amino-Imidazopyridine History as Janus Kinase Inhibitors and Their Pharmacological Use | |
US20060235013A1 (en) | Tricyclic azole derivatives | |
TWI729169B (zh) | 乙炔基衍生物 | |
JP3315144B2 (ja) | 置換イミダゾール−2−オンの誘導体及びその製造方法 | |
WO2021158698A1 (en) | Muscarinic receptor 4 antagonists and methods of use | |
CN118063429A (zh) | 作为btk抑制剂的吡啶酰胺类化合物 | |
AU2020428591A1 (en) | Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases | |
CN114751899B (zh) | 一种二芳基脲类mTOR激酶抑制剂及其药物组合物和应用 | |
EP3822266A1 (en) | Pyrrolidinyl urea derivatives and application thereof in trka-related diseases | |
AU2021398704A1 (en) | Heterocyclic jak inhibitor | |
CN118056832A (zh) | 具有btk抑制作用的吡唑并嘧啶衍生物 | |
CN118027035A (zh) | 作为btk抑制剂的嘌呤衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination |